# BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

> **NCT06167265** · PHASE1 · COMPLETED · sponsor: **Genovate Biotechnology Co., Ltd.,** · enrollment: 40 (actual)

## Conditions studied

- Intermittent Claudication

## Interventions

- **DRUG:** Cilostazol Tablet 100 mg
- **DRUG:** PMR Tablet 145 mg

## Key facts

- **NCT ID:** NCT06167265
- **Lead sponsor:** Genovate Biotechnology Co., Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-28
- **Primary completion:** 2023-12-22
- **Final completion:** 2024-01-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06167265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06167265, "BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06167265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*